Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.98 USD | +0.65% | -2.82% | +118.36% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is in a robust financial situation considering its net cash and margin position.
- The stock, which is currently worth 2024 to 0.31 times its sales, is clearly overvalued in comparison with peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 307.08 times its estimated earnings per share for the ongoing year.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+118.36% | 4.73B | - | ||
+8.25% | 9.23B | B- | ||
+4.49% | 6.8B | C+ | ||
+0.92% | 5.26B | C | ||
+0.68% | 2.4B | B+ | ||
-2.06% | 1.26B | C | ||
+104.86% | 826M | - | C | |
-3.70% | 812M | - | D+ | |
-3.98% | 144M | - | - | |
-23.46% | 57.24M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- OSCR Stock
- Ratings Oscar Health, Inc.